Patient Support

CHOOSE TREMFYA^®, GET TREMFYA^®

START WITH TREMFYA^®
SO SIMPLE TRIAL PROGRAM

The TREMFYA^® So Simple Trial Program provides patients their first dose of TREMFYA^® so they may determine with their provider if it is right for them.

FORM for easy enrollment

COST to patient

Shipment can be authorized within 3 BUSINESS DAYS after prescription.^*

This trial program is open to patients who have commercial insurance, government coverage, or no insurance coverage. However, there is no guarantee of continuous accessibility after the program ends.

^*Shipment can be authorized within 3 business days of submitting a prescription pending patient program opt-in and scheduling shipment.

FILL OUT AN ENROLLMENT FORM

FOR COMMERCIALLY INSURED PATIENTS STAY ON TREMFYA^®

JANSSEN CAREPATH SAVINGS PROGRAM

Eligible patients pay

per injection

with a $20,000 maximum program beneﬁt per calendar year

See full program requirements at Tremfya.JanssenCarePathSavings.com.

Patients will receive TREMFYA^® at no-cost until they receive insurance coverage approval

See full program requirements at JanssenCarePath.com/Tremfya/Janssen-Link.

Both programs are unavailable to individuals who use any state or federal government-funded healthcare program to cover a portion of medication costs, such as Medicare, Medicaid, TRICARE, Department of Defense, or Veterans Administration.

ACCESS EXPRESS ENROLLMENT

These programs are for medication only. Terms expire at the end of each program year and may change.

CONTRAINDICATIONS
TREMFYA^® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Infections
TREMFYA^® may increase the risk of infection. Treatment with TREMFYA^® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA^® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA^® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA^® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA^®. Initiate treatment of latent TB prior to administering TREMFYA^®. Monitor patients for signs and symptoms of active TB during and after TREMFYA^® treatment. Do not administer TREMFYA^® to patients with active TB infection.

Hypersensitivity Reactions
Serious hypersensitivity reactions have been reported with postmarket use of TREMFYA^®, some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA^® and initiate appropriate therapy.

Immunizations
Prior to initiating TREMFYA^®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA^®.

ADVERSE REACTIONS
Most common (≥1%) adverse reactions associated with TREMFYA^® include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

Please read the full Prescribing Information and Medication Guide for TREMFYA^®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v1